StreetInsider.com News Articles

BrainsWay Ltd. (BWAY) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 Revenue Guidance

Wed, 11 Mar 2026 07:32:34 -0400

BrainsWay Ltd. (NASDAQ: BWAY) reported Q1 EPS of $0.07, $0.02 better than the analyst estimate of $0.05. Revenue for the quarter came in at $14.5 million versus the consensus estimate of $14.02 million.

GUIDANCE:

BrainsWay Ltd. sees FY2026 revenue of $66-68 million, versus the consensus of $64.8 million.

For earnings history and earnings-related data on BrainsWay Ltd. (BWAY) click here.

BrainsWay Ltd. (BWAY) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 Revenue Guidance

Wed, 11 Mar 2026 07:32:34 -0400

GUIDANCE:

BrainsWay Ltd. sees FY2026 revenue of $66-68 million, versus the consensus of $64.8 million.

For earnings history and earnings-related data on BrainsWay Ltd. (BWAY) click here.

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Wed, 11 Mar 2026 07:30:00 -0400

Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million

Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage

Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million

Remaining Performance Obligations Increased 43% to Approximately $70 Million

Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth)

Form 6-K Brainsway Ltd. For: Mar 11

Wed, 11 Mar 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260311/26142641.html

Form 6-K Brainsway Ltd. For: Mar 11

Wed, 11 Mar 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260311/26142641.html

Form 6-K Brainsway Ltd. For: Mar 11

Wed, 11 Mar 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260311/26142641.html

Form 6-K Brainsway Ltd. For: Mar 04

Thu, 05 Mar 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260305/26114558.html

Form 6-K Brainsway Ltd. For: Mar 04

Thu, 05 Mar 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260305/26114558.html

Form 6-K Brainsway Ltd. For: Mar 04

Thu, 05 Mar 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260305/26114558.html

Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

Wed, 04 Mar 2026 07:30:00 -0400

BURLINGTON, Mass. and JERUSALEM, March 04, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) unveiled new clinical data showing a significantly faster, noninvasive way to treat depression without compromising the efficacy of one of psychiatry’s most impactful treatments. The milestone advances BrainsWay’s brain health vision and sets the stage for a neuromodulation platform that transforms lives.

Two new peer-reviewed manuscripts in Brain Stimulation found that BrainsWay’s exclusive FDA-cleared SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol for

Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

Wed, 04 Mar 2026 07:30:00 -0400

Two new peer-reviewed manuscripts in Brain Stimulation found that BrainsWay’s exclusive FDA-cleared SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol for

Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

Wed, 04 Mar 2026 07:30:00 -0400

Two new peer-reviewed manuscripts in Brain Stimulation found that BrainsWay’s exclusive FDA-cleared SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol for